Innate Pharma S.A. (IPHA)
| Market Cap | 349.63M |
| Revenue (ttm) | 96.42M |
| Net Income (ttm) | -23.32M |
| Shares Out | 78.97M |
| EPS (ttm) | -0.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $4.40 |
| Previous Close | $4.40 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 4.36 |
| Day's Range | 4.36 - 4.40 |
| Day's Volume | 2,239 |
| 52-Week Range | 3.55 - 8.23 |
Marseille, March 16, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conferen...
MARSEILLE, France, March 16, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a ...
MARSEILLE, France, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marc...
Marseille, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Fina...
MARSEILLE, France, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior mana...
Marseille, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management t...
Innate Pharma SA's (NASDAQ: IPHA) ongoing TELLOMAK Phase 2 trial, evaluating lacutamab has reached the pre-determined number of responses needed to advance to stage 2, thus allowing Innate to recruit ad...
TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated
Marseille, Feb. 09, 2021 (GLOBE NEWSWIRE) -- TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated
Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021 Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021
Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021 Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021
MARSEILLE, France, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decisi...
Marseille, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decision to pr...
MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior mana...
Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management t...
New York, New York--(Newsfile Corp. - December 22, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "C...
Innate Pharma, S.A.: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before December 22, 2020; click here to submit trade information Investors with losses are encouraged to contact the firm before December 22, 202...
LOS ANGELES, Dec. 21, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Innate Pharma S.A. ("Innate" or "the...
New York, New York--(Newsfile Corp. - December 21, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA) and cert...
New York, New York--(Newsfile Corp. - December 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...
NEW YORK--(BUSINESS WIRE)-- #classaction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United Sta...
LOS ANGELES--(BUSINESS WIRE)---- $IPHA #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action fil...
NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September ...
BENSALEM, Pa., Dec. 14, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on beha...
NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are advised to...
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 an...
MARSEILLE, France, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return the US and ...
Marseille, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return the US and EU comme...
New York, New York--(Newsfile Corp. - December 9, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10,...
LOS ANGELES, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed ...
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from ...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are advised to c...
New York, New York--(Newsfile Corp. - December 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...
Phase 2 expansion cohort data supports ongoing Phase 3 trial Phase 2 expansion cohort data supports ongoing Phase 3 trial
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA). Such investors are advised to contac...
MARSEILLE, France, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial calendar:
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8...
LOS ANGELES, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed ...
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from ...
New York, New York--(Newsfile Corp. - November 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...
Marseille, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its revenues and cash position for the ...
NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September ...
Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options Priority Medicines (PRIME) designation supports the poten...
MARSEILLE, France, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that members of its senior man...
New York, New York--(Newsfile Corp. - November 9, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...
New York, New York--(Newsfile Corp. - November 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...
New York, New York--(Newsfile Corp. - November 6, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "Co...
BENSALEM, Pa.--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)
LOS ANGELES--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)
About IPHA
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the trea... [Read more...]
| Industry Biotechnology | IPO Date Oct 17, 2019 |
| CEO Mondher Mahjoubi | Country France |
| Stock Exchange NASDAQ | Ticker Symbol IPHA |
Analyst Forecasts
According to 5 analysts, the average rating for Innate Pharma stock is "Buy." The 12-month stock price forecast is 7.30, which is an increase of 65.91% from the latest price.